Delta-Fly Pharma, Inc.
DeltaーFly Pharma株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4598
FY2025 (Mar 2026) · J-GAAP · parent-only (non-consolidated) Source: filing S100YJOM
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2025 (Mar 2026) runs Apr 1, 2025 – Mar 31, 2026.
| Gross margin | —Not in the filing: revenue, gross profit / cost of sales |
|---|---|
| Operating margin | —Not in the filing: revenue |
| Net margin | —Not in the filing: revenue |
| Return on equity | -1059.8%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | -477.5% |
| Revenue growth (YoY) | —Not in the filing: revenue |
| EPS (basic) | −¥140.45 |
| EPS growth (YoY) | —Base is zero or negative |
| Current ratio | 0.98x |
| Equity ratio | 12.6% |
| Book value / share | ¥2.35 |
| Free cash flow | —Not in the filing: capital expenditure (PP&E + intangible assets) |